Cerebrolysin for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Cerebrolysin for Health & Longevity

Created on 09/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Injected protein fragments from pig brain, built to imitate the body's own nerve-repair signals. Results come from recovery after stroke, head injury, or dementia, much of that evidence manufacturer-funded; none in people without brain disease. Use means repeated infusions, imported supply, expense, and a rare but severe allergic reaction. (Full Review)

Protocol

Standard licensed course
10–30 mL daily
5 days weekly, 4 weeks, 2–4 cycles yearly; 20–50 mL, 10–30 days after stroke.
Route and rate
Intravenous infusion
Up to 10 mL by slow injection; above that, diluted and infused in 15 minutes.
Best time of day
Morning
Agitation is a common reaction, and vertigo falls in waking hours.
Time to effect
Arm and hand function after stroke
90 days
After 30 mL daily for three weeks with standardised rehabilitation.
Neurological recovery after stroke
21–30 days
On the clinician-rated stroke severity scale, started within 72 hours.
Cognition in dementia
4 weeks
Largest signal at four weeks; the advantage faded by six months.

Benefits

Contraindications
  • Hypersensitivity to any component or porcine protein
  • Epilepsy or history of status epilepticus
  • Severe renal impairment (eGFR below 30 mL/min/1.73 m²)
  • Pregnancy or breastfeeding
  • Under 18
  • No access to sterile administration by a practitioner
    •
Key Interactions
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine): additive stimulation
  • Antidepressants generally (SSRIs such as sertraline): overlapping agitation
  • Stimulant nootropics (caffeine, alpha-GPC, racetams): additive agitation and insomnia
  • Supplements with additive amino-acid or excitatory load (glutamine, taurine): additive agitation
  • Over-the-counter sedating antihistamines (diphenhydramine) and alcohol: additive dizziness
  • Balanced amino acid infusion solutions (Aminoplasmal, Vamin): incompatible in one line
  • Vitamin and cardiovascular drug infusions (thiamine, furosemide): never mixed in one container
  • Cholinesterase inhibitors (donepezil, rivastigmine): additive nausea
    •

Risk & Side Effects

  • High: Excess non-fatal serious adverse events at higher cumulative dose; vertigo and dizziness
  • Medium: Agitation and restlessness; heat, flushing and sweating during administration
  • Low: Headache; nausea; transient low mood and apathy; anaphylaxis and hypersensitivity
  • Speculative: Seizure provocation in epilepsy; infectious transmission from porcine material; injection-site infection; growth-factor signalling and tumour biology; counterfeit grey-market product

Monitoring

Marker Target Why
eGFR ≥ 90 mL/min/1.73 m²; below 30 contraindicated Gates eligibility for treatment
Serum creatinine 0.6–1.0 mg/dL women, 0.7–1.2 men; stable Input to eGFR; detects filtration change
ALT 10–26 U/L women, 10–33 men Safety check on repeated courses
Serum tryptase < 8 ng/mL at baseline Predisposition to severe hypersensitivity
hs-CRP < 1.0 mg/L Inflammatory state proposed to be damped
Serum BDNF No target; track change from own baseline The only biomarker moved in humans
MoCA ≥ 26 of 30; change from baseline matters more Shows whether cognitive change occurred

Cadence: Baseline before a first course; renal and liver panels before each cycle; cognitive score four weeks and six months after a course; blood pressure and heart rate during each cycle's first infusion.

Qualitative Assessment

  • Sleep onset latency and night-time waking, especially in a cycle's first week
  • Word-finding fluency and speed of recall in ordinary conversation
  • Sustained attention on a demanding task, and how long it holds before fatigue
  • Mood, irritability, and restlessness in the hours following each infusion
  • Dizziness, unsteadiness, or near-falls in the four hours after a dose
  • Skin flushing, itching, or throat tightness during administration
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.